# Cephagenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cephagenix

- Industry: Pharmaceuticals
- Headquarters: Glostrup, Denmark
- Website: www.cephagenix.com
- Total disclosed funding: $9.3M
- Latest round: Seed (Jan 15, 2025)
- Investors on record: 2

## About

Founded in 2020 by Jes Olesen, and based in Glostrup, Denmark, Cephagenix, formed as a joint venture between JOHealth ApS and Saniona A/S., is a biotechnology company focused on developing innovative migraine treatments, aiming to improve patient outcomes through advanced therapeutic agents targeting migraine mechanisms. In January 2025, Cephagenix raised EUR 9 million in seed funding co-led by AbbVie Biotech Ventures and AdBio Partners.

The firm specializes in creating first-in-class KATP channel inhibitors, aiming to provide safe and effective options for migraine relief. 

The revenue model for Cephagenix is structured around partnerships with healthcare providers and pharmaceutical distributors, ensuring a steady flow of products to various markets. Transactions typically occur through direct sales to clinics and hospitals, as well as through retail channels where their products can be purchased by consumers. 

The company plans to use the January 2025 funds to enhance its product line with new migraine therapies, aiming for market launch in the upcoming years. Cephagenix is also pursuing expansion into additional European markets and North America, with specific regions targeted for late 2025. The recent funding will be utilized to accelerate product development and broaden its reach in these areas.

## Funding rounds

- Seed, Jan 15, 2025, $9.3M — AbbVie Ventures, AdBio Partners

## Investors

- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Seed
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed